Start
Features
Free trial / FAQ

Researchers
Physicians
Pharmacists
Ecotrophologists
Product Managers
in Health Industries

Loading…

Medical Research Finder

Legal Notice
Privacy
Terms of Use

meRfi® Microbiome - The Digital Gut Microbiome Reference (incl. AI Chat)
Prebiotics, Probiotics, FMT / Manipulators of the Intestinal Microbiota

AuthorsReferences (Sources)

meRfi® AI Chat

Limosilactobacillus reuteri & Type 2 diabetes (T2D)

Welcome to meRfi Microbiome!

Please register to continue your trial period!

meRfi Microbiome provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.

Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.

Start your free trial and transform your understanding of the gut microbiota today!

(Login)

Navigation

Clinical data

XXX - Limosilactobacillus reuteri DSM 17938 & Type 2 diabetes (T2D)

In this randomized, double-blind clinical trial, it was found that after 12 weeks of consuming Limosilactobacillus reuteri DSM 17938, there was no change in HbA1c levels among individuals with type 2 diabetes who were undergoing insulin therapy. This was the primary objective of the trial (1).

References

(1) Mobini et al. 2017 Diabetes Obes Metab 19(4): 579-589

see also:
[Probiotics (living agents) & Type 2 Diabetes (T2D)](brain://nCQhJ3hVpk6mMNOloJy…

References (Sources)

Metabolic effects of Lactobacillus reuteri DSM 17938 in people with type 2 diabetes: a randomized controlled trial
Mobini et al. 2017 Diabetes Obes Metab 19(4): 579-589

AI Chat

7/1/2026

Chat with our artificial intelligence:

Start chat!